Rock-One International of Hong Kong partnered with BioLight Israeli Life Sciences (TASE: BOLT; OTCQX:BLGTY), an Israeli medical device company, to commercialize BioLight devices for ophthalmology and oncology in China (see story). As part of the deal, Rock-One invested $6.2 million in BioLight, buying a 19% stake in the company, paying a 12% premium to the 30-day average closing price. In addition, the two companies will form a manufacturing JV, which will be financially supported entirely by Rock-One, to make BioLight devices in China for the China market.